CanSino Biologics Inc is a CN-based company operating in Biotechnology industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,105 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The firm is also engaged in the research and development of pharmaceutical production processes. The firm conducts its business in the domestic and overseas markets.
Follow-Up Questions
Who is the CEO of CanSino Biologics Inc?
Mr. Xuefeng Yu is the Executive Chairman of the Board of CanSino Biologics Inc, joining the firm since 2009.
What is the price performance of CASBF stock?
The current price of CASBF is $6.6, it has decreased 0% in the last trading day.
What are the primary business themes or industries for CanSino Biologics Inc?
CanSino Biologics Inc belongs to Biotechnology industry and the sector is Health Care
What is CanSino Biologics Inc market cap?
CanSino Biologics Inc's current market cap is $1.6B
Is CanSino Biologics Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for CanSino Biologics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
